Pfizer Ltd
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India.[1]
It is the 3rd largest multinational pharmaceutical company in India.[2]
- Market Cap ₹ 23,906 Cr.
- Current Price ₹ 5,226
- High / Low ₹ 6,453 / 3,950
- Stock P/E 39.1
- Book Value ₹ 820
- Dividend Yield 0.67 %
- ROCE 22.0 %
- ROE 16.1 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 35.5%
Cons
- The company has delivered a poor sales growth of 1.05% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Multinational
Part of BSE 250 SmallCap Index BSE 400 MidSmallCap Index Nifty 500 Multicap 50:25:25 BSE Allcap BSE SmallCap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1,049 | 1,112 | 1,853 | 2,012 | 1,966 | 1,969 | 2,082 | 2,152 | 2,239 | 2,611 | 2,425 | 2,193 | 2,238 | |
865 | 872 | 1,438 | 1,579 | 1,616 | 1,468 | 1,516 | 1,578 | 1,526 | 1,775 | 1,616 | 1,555 | 1,529 | |
Operating Profit | 184 | 239 | 414 | 433 | 350 | 501 | 566 | 574 | 712 | 836 | 809 | 638 | 709 |
OPM % | 18% | 22% | 22% | 22% | 18% | 25% | 27% | 27% | 32% | 32% | 33% | 29% | 32% |
519 | 109 | 44 | 97 | 232 | 114 | 167 | 183 | 81 | 63 | 134 | 185 | 204 | |
Interest | 2 | 1 | 2 | 1 | 2 | 1 | 2 | 11 | 15 | 11 | 13 | 15 | 14 |
Depreciation | 8 | 8 | 250 | 58 | 63 | 66 | 71 | 103 | 109 | 115 | 106 | 62 | 61 |
Profit before tax | 694 | 340 | 207 | 470 | 517 | 548 | 660 | 642 | 669 | 773 | 824 | 746 | 838 |
Tax % | 27% | 35% | 66% | 35% | 35% | 34% | 35% | 21% | 26% | 21% | 24% | 26% | |
503 | 221 | 70 | 305 | 337 | 360 | 429 | 509 | 498 | 613 | 624 | 551 | 618 | |
EPS in Rs | 168.62 | 74.01 | 15.26 | 66.67 | 73.62 | 78.71 | 93.79 | 111.29 | 108.77 | 133.90 | 136.38 | 120.52 | 135.06 |
Dividend Payout % | 19% | 486% | 82% | 22% | 27% | 25% | 24% | 297% | 32% | 26% | 51% | 29% |
Compounded Sales Growth | |
---|---|
10 Years: | 7% |
5 Years: | 1% |
3 Years: | -1% |
TTM: | -3% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | 5% |
3 Years: | 3% |
TTM: | 15% |
Stock Price CAGR | |
---|---|
10 Years: | 11% |
5 Years: | 5% |
3 Years: | 2% |
1 Year: | 28% |
Return on Equity | |
---|---|
10 Years: | 16% |
5 Years: | 18% |
3 Years: | 19% |
Last Year: | 16% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 30 | 30 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 | 46 |
Reserves | 1,665 | 629 | 1,927 | 2,118 | 2,373 | 2,637 | 2,966 | 3,350 | 2,347 | 2,819 | 3,162 | 3,550 | 3,705 |
0 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 63 | 39 | 41 | 40 | 37 | |
365 | 318 | 638 | 722 | 840 | 1,004 | 926 | 1,007 | 810 | 997 | 752 | 593 | 671 | |
Total Liabilities | 2,060 | 977 | 2,614 | 2,888 | 3,261 | 3,690 | 3,940 | 4,405 | 3,266 | 3,901 | 4,001 | 4,229 | 4,459 |
26 | 20 | 944 | 925 | 902 | 950 | 886 | 973 | 894 | 869 | 749 | 713 | 689 | |
CWIP | 0 | 3 | 13 | 3 | 15 | 1 | 0 | 1 | 3 | 1 | 8 | 0 | 3 |
Investments | 46 | 44 | 43 | 37 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
1,988 | 909 | 1,614 | 1,923 | 2,343 | 2,739 | 3,054 | 3,432 | 2,369 | 3,030 | 3,244 | 3,516 | 3,767 | |
Total Assets | 2,060 | 977 | 2,614 | 2,888 | 3,261 | 3,690 | 3,940 | 4,405 | 3,266 | 3,901 | 4,001 | 4,229 | 4,459 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-16 | 132 | 113 | 345 | 329 | 332 | 98 | 323 | 427 | 667 | 356 | 257 | |
626 | 103 | 68 | -701 | -250 | -238 | 35 | 1,530 | -469 | -575 | -36 | 54 | |
-43 | -1,360 | -1 | -62 | -83 | -110 | -110 | -164 | -1,571 | -181 | -346 | -235 | |
Net Cash Flow | 567 | -1,125 | 181 | -417 | -3 | -17 | 23 | 1,690 | -1,613 | -88 | -26 | 75 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 49 | 57 | 32 | 26 | 20 | 29 | 30 | 29 | 18 | 20 | 23 | 31 |
Inventory Days | 181 | 148 | 191 | 167 | 148 | 147 | 189 | 198 | 199 | 173 | 175 | 200 |
Days Payable | 165 | 156 | 165 | 157 | 178 | 245 | 213 | 197 | 130 | 102 | 91 | 77 |
Cash Conversion Cycle | 65 | 49 | 58 | 36 | -10 | -69 | 6 | 31 | 87 | 91 | 107 | 154 |
Working Capital Days | 7 | 25 | 7 | -9 | -46 | -57 | -15 | -7 | 13 | -8 | 3 | 31 |
ROCE % | 19% | 29% | 24% | 22% | 17% | 21% | 23% | 20% | 23% | 29% | 26% | 22% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 19 Nov
-
Announcement under Regulation 30 (LODR)-Change in Management
14 Nov - Appointment of Mr. Chetan Solse as India Legal Lead.
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 12 Nov
-
Announcement under Regulation 30 (LODR)-Change in Directorate
10 Nov - Completion of terms for two Independent Directors.
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 7 Nov
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
Concalls
-
Aug 2020TranscriptPPT
-
May 2017TranscriptPPT
-
Feb 2017TranscriptPPT
-
Nov 2016TranscriptPPT
-
Aug 2016TranscriptPPT
-
May 2016TranscriptPPT
-
Feb 2016TranscriptPPT
Product Portfolio
Presently, the company sells ~150 different products across 15+ therapeutic areas viz. anti-allergic, anti-diabetic, anti-infectives, cardiovascular, gastrointestinal, neurology, pain, respiratory, vitamin/minerals, antibiotics, etc.[1][2]